Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sox4 siRNA
- Development stage
- Unknown
- Lead developer
- University of British Columbia
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Sox4 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the SRY-box transcription factor 4 (SOX4) through RNA interference. SOX4 is a transcription factor involved in embryonic development and cell differentiation, and its deregulation is linked to various cancers. In research involving cutaneous melanoma, Sox4 siRNA has been utilized to investigate the gene's role in tumor progression. Studies have shown that knocking down SOX4 in melanoma cell lines, such as MMRU, can lead to increased cell migration, suggesting that SOX4 may act as a tumor suppressor or modulator of metastasis in certain contexts. While it serves as a valuable research tool for functional genomics, its potential as a therapeutic agent or prognostic marker continues to be explored in preclinical models.
- Other names
- Sox4 small interfering RNASox-4 small interfering RNASox 4 small interfering RNAsiRNA targeting Sox4
02
Targets
SOX4 (SRY-box transcription factor 4)
Beyond the preview
Go deeper on Sox4 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sox4 siRNA.